Assessment of no reflow phenomenon after acute myocardial infarction using harmonic angio and intravenous pump infusion with Levovist: comparison with intracoronary contrast injection

Myocardial contrast echocardiography (intracoronary application) has emerged as an accurate method to detect the “no-reflow phenomenon.” To investigate the diagnostic value of harmonic angiography after intravenous infusion of Levovist in assessing “no-reflow,” both intracoronary and intravenous contrast injections were performed in a group of patients with acute myocardial infarction. Seventeen consecutive patients with a successfully reperfused acute myocardial infarction within 6 hours of symptom onset were selected for this study. All patients underwent contrast echocardiography with harmonic angiography with Levovist (400 mg/mL, intravenous pump infusion, trigger intervals 1:4 to 1:8) and sonicated albumin (0.5 to 1 mL, intracoronary bolus) on day 1 after the achievement of a sustained coronary reflow. Myocardial perfusion was qualitatively assessed with a 12-segment model. The endocardial length of the residual contrast defect after reflow was also calculated. Forty-four of 204 segments were not analyzed after intravenous contrast echocardiography and 37 after intracoronary contrast echocardiography because of artifacts. Intracoronary and intravenous injections showed a perfusion defect in 31 (19%) segments, with a concordance of 89% (κ coefficient, 0.72). Concordance in anteroseptal, anterolateral, and inferolateral segments was 95% (κ = 0.92), 88% (κ = 0.66), and 83% (κ = 0.57), respectively. With intracoronary injection used as the reference method, intravenous injection had a sensitivity of 74% and a specificity of 93% for diagnosing contrast defects. The endocardial extent of no-reflow was 18 ± 19 after intravenous and 21 ± 17 after intracoronary contrast echocardiography (P = not significant). Intravenous contrast echocardiography with Levovist reliably identifies the no-reflow phenomenon after successful reperfusion, especially in acute anteroseptal myocardial infarction. (J Am Soc Echocardiogr 2001;14:773-81.)